trending Market Intelligence /marketintelligence/en/news-insights/trending/rmxhkyO9yKiFKYuQ_a5vaQ2 content esgSubNav
In This List

Bristol-Myers Squibb, Incyte to initiate phase 3 trials for cancer treatment

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


Bristol-Myers Squibb, Incyte to initiate phase 3 trials for cancer treatment

Bristol-Myers Squibb Co. and Incyte Corp. agreed to advance a combination of their cancer treatments in phase 3 trials involving patients with first-line non-small cell lung cancer and first-line head and neck cancer.

The trials will evaluate Bristol-Myers' Opdivo with Incyte's investigational epacadostat treatment.

Further, the companies are expanding their Echo-2014 phase 1/2 study to include anti-PD-1/PD-L1 relapsed/refractory melanoma cohorts. The expanded program and the phase 3 registrational studies will be co-funded by the two companies.